Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
April 17 2018 - 6:26PM
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a clinical stage
biopharmaceutical company focused on discovering and developing
cellular immunotherapies for cancers and orphan inherited blood
disorders, today announced the pricing of an underwritten public
offering of 8,000,000 shares of its common stock at a price to the
public of $7.50 per share. The aggregate offering size, before
deducting the underwriting discounts and commissions and other
offering expenses, is expected to be approximately $60.0 million.
The offering is expected to close on or about April 20, 2018,
subject to customary closing conditions. In addition, the
underwriters have been granted a 30-day option to purchase up to an
additional 1,200,000 shares of its common stock at the public
offering price, less the underwriting discounts and commissions.
Citigroup and Jefferies are acting as lead book-running managers
for the offering. Guggenheim Securities, Ladenburg Thalmann and
Raymond James are acting as co-managers.
The securities described above are being offered by Bellicum
pursuant to a shelf registration statement filed by Bellicum with
the Securities and Exchange Commission (SEC), which was declared
effective on July 12, 2017. A preliminary prospectus supplement
related to the offering was filed with the SEC and is available for
free on the SEC’s website at http://www.sec.gov. Copies of the
final prospectus supplement and the accompanying prospectus related
to this offering, when available, may be obtained from: Citigroup
Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, or by telephone at (800)
831-9146; or Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or
by telephone at (877) 821-7388, or by e-mail at
Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Bellicum Pharmaceuticals, Inc.
Bellicum is a clinical stage biopharmaceutical company focused
on discovering and developing cellular immunotherapies for cancers
and orphan inherited blood disorders. Bellicum is using its
proprietary Chemical Induction of Dimerization (CID) technology
platform to engineer and control components of the immune system.
Bellicum is developing next-generation product candidates in some
of the most important areas of cellular immunotherapy, including
CAR-T, TCR, and hematopoietic stem cell transplantation (HSCT)
therapies. Bellicum is based in Houston, Texas.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as “predicts,” “believes,” “potential,”
“proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“expected,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things, the completion, timing and size of
its public offering. Various factors may cause differences between
Bellicum’s expectations and actual results, including risks and
uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the public
offering, as well as those discussed in greater detail in
Bellicum’s filings with the SEC, including without limitation in
its Form 10-K for the year ended December 31, 2017. Any
forward-looking statements that are made in this press release
speak only as of the date of this press release. Bellicum assumes
no obligation to update the forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
Bellicum Pharmaceuticals
Investors:
Bellicum Pharmaceuticals, Inc., Alan Musso, CFO
832-384-1116
amusso@bellicum.com
Media:
BMC Communications, Brad Miles, 646-513-3125
bmiles@bmccommunications.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Sep 2023 to Sep 2024